This archive contains the following articles listed by volume, issue and page number:
 |
|
|
Volume 12, 2008 Articles |
Title (Click for Details) |
Vol/Issue |
Page |
PreScription: Year Number 12…And Still Much Work to Do |
Vol. 12 No. 1 |
4 |
Intravitreal Bevacizumab for Choroidal Neovascularization in Age-Related Macular Degeneration |
Vol. 12 No. 1 |
8 |
Cancer-Related Terminology: Glossaries for Compounding Pharmacists and Their Clients |
Vol. 12 No. 1 |
16 |
Hospice and Compounding Pharmacy: Once Inseperable |
Vol. 12 No. 1 |
28 |
Disposing of Expired Drugs and Chemicals: New Options for Compounders |
Vol. 12 No. 1 |
38 |
Websites: Keeping Current in 2008 |
Vol. 12 No. 1 |
48 |
Quality-Control Analytical Methods: Stability Versus Potency Testing: The Madness is in the Method |
Vol. 12 No. 1 |
50 |
Basics of Compounding: Considerations for Implementing United States Pharmacopeia Chapter <797> Pharmaceutical Compounding--Sterile Preparations, Part 5: Verification of Accuracy, Sterility, and Sterilization of Compounded Preparations |
Vol. 12 No. 1 |
54 |
Calculations: Compounding for Cancer Patients |
Vol. 12 No. 1 |
62 |
Standard Operating Procedure: Compliance with the Health Insurance Portability and Accountability Act (HIPAA) of 1996 |
Vol. 12 No. 1 |
63 |
Cyclosporine Topical Gel |
Vol. 12 No. 1 |
64 |
Diclofenac Sodium 1% Soft-Patch Gel |
Vol. 12 No. 1 |
65 |
Diclofenac Sodium 1% Soft-Patch Lipophilic Gel |
Vol. 12 No. 1 |
66 |
Diltiazem 5% in Lipoderm, Veterinary |
Vol. 12 No. 1 |
67 |
Emetine Hydrochloride 30-mg/mL Injection |
Vol. 12 No. 1 |
68 |
Flosulide 10-mg/mL Injection |
Vol. 12 No. 1 |
69 |
Pentoxifylline 20-mg/mL Oral Suspension |
Vol. 12 No. 1 |
70 |
Piroxicam 1% Soft-Patch Lipophilic Gel |
Vol. 12 No. 1 |
71 |
Piroxicam 1% Soft-Patch Topical Gel |
Vol. 12 No. 1 |
72 |
Trimethoprim 10-mg/mL Oral Suspension |
Vol. 12 No. 1 |
73 |
Specialty Compounding for Improved Patient Care: 2006 National Survey of Compounding Pharmacists |
Vol. 12 No. 1 |
74 |
Room Temperature Stability of Injectable Succinylcholine Dichloride |
Vol. 12 No. 1 |
83 |
2007 Reviewers |
Vol. 12 No. 1 |
86 |
PostScription: Consumer Options for Disposal of Unused Medications |
Vol. 12 No. 1 |
87 |
PreScription: Compounding Around the World |
Vol. 12 No. 2 |
92 |
Current Compounding Practices in Europe |
Vol. 12 No. 2 |
94 |
Compounding Around the World |
Vol. 12 No. 2 |
102 |
Establishing a Quality-Assurance Program for Hospital Compounding |
Vol. 12 No. 2 |
116 |
Hormone Therapy: It's Time for a Second Opinion |
Vol. 12 No. 2 |
122 |
Newsletters: An Essential Marketing Tool |
Vol. 12 No. 2 |
128 |
Quality-Control Analytical Methods: Minimizing the Probability of Out-of-Specification Preparations: Results that Make You Say…Hmmm! |
Vol. 12 No. 2 |
130 |
Basics of Compounding: Considerations for Implementing United States Pharmacopeia Chapter <797> Pharmaceutical Compounding--Sterile Preparations, Part 6: 2008 Revisions to Chapter <797> |
Vol. 12 No. 2 |
136 |
Calculations |
Vol. 12 No. 2 |
145 |
Acyclovir 5% Topical Ointment |
Vol. 12 No. 2 |
146 |
Alum 6.5% Topical Cream |
Vol. 12 No. 2 |
147 |
Aminacrine Hydrochloride 0.1% Cream |
Vol. 12 No. 2 |
148 |
Butesin Picrate 1% ointment |
Vol. 12 No. 2 |
149 |
Carbamazepine Topical Preparations |
Vol. 12 No. 2 |
150 |
Chlorhexidine Gel |
Vol. 12 No. 2 |
151 |
EDTA 1% Cream |
Vol. 12 No. 2 |
152 |
Erythromycin 1% and Neomycin Sulfate Ointment |
Vol. 12 No. 2 |
153 |
Heparin Gel-Cream |
Vol. 12 No. 2 |
154 |
Hydrogen Peroxide 8% Cream |
Vol. 12 No. 2 |
155 |
Compatibility and Stability of Palonosetron Hydrochloride with Four Neuromuscular Blocking Agents During Simulated Y-Site Administration |
Vol. 12 No. 2 |
156 |
Chemical Stability of Tramadol Hydrochloride Injection |
Vol. 12 No. 2 |
161 |
Pharmaceutical Development of Enteric-Release Hard Gelatin Capsules in the Compounding Setting |
Vol. 12 No. 2 |
163 |
Compatibility and Stability of Palonosetron Hydrochloride with Gentamicin, Metronidazole, or Vancomycin During Simulated Y-Site Administration |
Vol. 12 No. 2 |
170 |
PostScription: Accreditation by the Pharmacy Compounding Accreditation Board: Raising the Bar for Patient Care |
Vol. 12 No. 2 |
174 |
PreScription: Pain! |
Vol. 12 No. 3 |
180 |
Topical Treatment of Neuropathic Pain |
Vol. 12 No. 3 |
182 |
Compounded Local Anesthetics to Minimize Pain from Medical Procedures |
Vol. 12 No. 3 |
192 |
Dilution and Compounding of Ziconotide for Intrathecal Administration |
Vol. 12 No. 3 |
200 |
Pharmacy Compounding at the University of Connecticut: Secundum Artem et Scientia |
Vol. 12 No. 3 |
208 |
Developing and Implementing a Clinical Pharmacy Rotation in a Community Compounding Pharmacy |
Vol. 12 No. 3 |
213 |
Microbial Air-Sampling Equipment, Part 1: Meeting United States Pharmacopeia Chapter <797> Standards |
Vol. 12 No. 3 |
216 |
Communication with Pharmacy Technicians: How to Reduce Stress and Improve Pharmacy Operations |
Vol. 12 No. 3 |
230 |
Obtaining Accreditation by the Pharmacy Compounding Accreditation Board, Part 3: Developing a Program of Quality Assurance and Continuous Quality Improvement |
Vol. 12 No. 3 |
234 |
Litigating the Legality of Compounding: The Medical Center Pharmacy Case |
Vol. 12 No. 3 |
238 |
Developing a Niche Marketing Strategy |
Vol. 12 No. 3 |
242 |
Web 2.0 and Health 2.0: Are You In? |
Vol. 12 No. 3 |
244 |
A Process Verification Model for Quality Assurance in a Compounding Pharmacy |
Vol. 12 No. 3 |
247 |
Basics of Compounding: Considerations for Implementing United States Pharmacopeia Chapter <797> Pharmaceutical Compounding--Sterile Preparations, Part 7: Microbial Contamination Risk Levels, 12-Hour Use, and Immediate Use |
Vol. 12 No. 3 |
252 |
Calculations |
Vol. 12 No. 3 |
258 |
Standard Operating Procedure: Dealing with Patients Experiencing Pain: Presenting without a Prescription |
Vol. 12 No. 3 |
259 |
African Scalp Lotion |
Vol. 12 No. 3 |
260 |
Benzyl Benzoate Lotion |
Vol. 12 No. 3 |
261 |
Calcium Gluconate 2.5% Topical Gel |
Vol. 12 No. 3 |
262 |
Lubricating Gel |
Vol. 12 No. 3 |
263 |
Meloxicam 0.3% Topical Gel |
Vol. 12 No. 3 |
264 |
Miconazole Nitrate 2%, Deoxy-D-Glucose 0.2%, and Hydrocortisone 0.4% Lip Balm |
Vol. 12 No. 3 |
265 |
Potassium Nitrate/Benzocaine/Tetracaine Dental Gel |
Vol. 12 No. 3 |
266 |
Promethazine Hydrochloride 2.5-mg/mL Rectal Solution |
Vol. 12 No. 3 |
267 |
Tolnaftate 1% Antifungal Microemulsion |
Vol. 12 No. 3 |
268 |
Valsartan 4-mg/mL Oral Liquid |
Vol. 12 No. 3 |
269 |
Evaluation of the Percutaneous Absorption of Promethazine Hydrochloride, In Vitro, Using the Human Ex Vivo Skin Model |
Vol. 12 No. 3 |
270 |
Chemical Stability of Naltrexone Hydrochloride Injection |
Vol. 12 No. 3 |
274 |
Compatibility of Caspofungin Acetate Injection with Other Drugs During Simulated Y-Site Coadministration |
Vol. 12 No. 3 |
276 |
PostScription: A Contemporary Perspective on Compounding Education |
Vol. 12 No. 3 |
279 |
PreScription: First Estriol, Then What? |
Vol. 12 No. 4 |
284 |
Estriol: Women's Choice vs. A Manufacturer's Greed |
Vol. 12 No. 4 |
286 |
Transdermal Progesterone: Effects on Menopausal Symptoms and on Thrombotic, Anticoagulant, and Inflammatory Factors in Postmenopausal Women |
Vol. 12 No. 4 |
295 |
The Magic of Magnesium |
Vol. 12 No. 4 |
306 |
Progesterone and Traumatic Brain Injury: A Review of Literature |
Vol. 12 No. 4 |
310 |
Beyond-Use Dating, Labeling, Delivery, and Storage of Compounded and Repackaged Mediations in a Hospital or Institutional Setting |
Vol. 12 No. 4 |
316 |
Microbial Air-Sampling Equipment, Part 2: Experiences of Compounding Pharmacists |
Vol. 12 No. 4 |
321 |
Recommendations for Overcoming Barriers to Medication Therapy Management Implementation, Part 1: Review of Literature |
Vol. 12 No. 4 |
329 |
Using Readily Available Technology to Start or Enhance Pharmacy-Based Immunization |
Vol. 12 No. 4 |
334 |
Marketing for Your Community |
Vol. 12 No. 4 |
338 |
Quality-Control Analytical Methods: Homogeneity of Dosing Forms |
Vol. 12 No. 4 |
340 |
Basics of Compounding: Considerations for Implementing United States Pharmacopeia Chapter <797> Pharmaceutical Compounding--Sterile Preparations, Part 8; Stability and Beyond-Use Dating |
Vol. 12 No. 4 |
344 |
Calculations |
Vol. 12 No. 4 |
354 |
Chloroxylenol 1% and Chlorhexidine Diacetate 1% Topical Powder |
Vol. 12 No. 4 |
355 |
Silicone Cream |
Vol. 12 No. 4 |
356 |
Sodium Chloride 0.9% Ointment |
Vol. 12 No. 4 |
357 |
Squalene 0.2% Cream |
Vol. 12 No. 4 |
358 |
Sucralfate and Hyaluronic Acid Ointment |
Vol. 12 No. 4 |
359 |
Tretinoin and (-)Alpha-Bisabolol Gel |
Vol. 12 No. 4 |
360 |
Tretinoin and Dexpanthenol Gel |
Vol. 12 No. 4 |
361 |
Ultrasonic Adhesive Gel |
Vol. 12 No. 4 |
362 |
Vitamin A Suppository |
Vol. 12 No. 4 |
363 |
Zirconium Oxide Lotion |
Vol. 12 No. 4 |
364 |
Lack of Commercial Oral Drug Formulations for Children in Two Hospital Group Purchasing Agreements in France and Canada |
Vol. 12 No. 4 |
365 |
Physical and Chemical Stability of Palonosetron Hydrochloride with Glycopyrrolate and Neostigmine During Simulated Y-Site Administration |
Vol. 12 No. 4 |
368 |
Chemical Stability of Perphenazine in Two Commercially Available Vehicles for Oral Liquid Dosage Forms |
Vol. 12 No. 4 |
372 |
PostScription: It Is Not Just What You Say…But How You Say It! |
Vol. 12 No. 4 |
375 |
PreScription: Compounding Around the World |
Vol. 12 No. 5 |
382 |
Canine Public Servants: Caring for Drug Detection Dogs |
Vol. 12 No. 5 |
384 |
Transdermal Amlodipine Besylate in Lipoderm for the Treatment of Feline Hypertension: A Report of Two Cases |
Vol. 12 No. 5 |
392 |
Veterinary Compounding for Myasthenia Gravis |
Vol. 12 No. 5 |
398 |
Equine Anesthesia: Triple Drip |
Vol. 12 No. 5 |
402 |
Publication Expansion of United States Pharmacopeial Convention's Veterinary Standards and Clinical Information |
Vol. 12 No. 5 |
405 |
Golden Ticket to the United States Pharmacopeial Convention's Veterinary Internship |
Vol. 12 No. 5 |
410 |
Medication Therapy Management Implementation, Part 2: Study Methodologies, Barriers, and Recommendations to Overcome Barriers |
Vol. 12 No. 5 |
414 |
Insurance for the Compounding Pharmacy Business, Part 1: Who Is Covered? |
Vol. 12 No. 5 |
420 |
Excipient Choices for Special Populations |
Vol. 12 No. 5 |
426 |
Obtaining Accreditation by the Pharmacy Compounding Accreditation Board, Part 4L Tips for "Last Minute" Preparations |
Vol. 12 No. 5 |
432 |
Technology for the Patient-Centric Pharmacy |
Vol. 12 No. 5 |
434 |
Marketing: Taking Your Show on the Road |
Vol. 12 No. 5 |
438 |
Basics of Compounding: Considerations for Implementing United States Pharmacopeia Chapter <797> Pharmaceutical Compounding--Sterile Preparations, Part 9: Immediate-Use Compounded Sterile Preparations |
Vol. 12 No. 5 |
440 |
Calculations |
Vol. 12 No. 5 |
444 |
Aceclofenac 1.5% Gel-Cream |
Vol. 12 No. 5 |
446 |
Acetaminophen 10-mg/mL Rectal Solution |
Vol. 12 No. 5 |
447 |
Carnitine 400-mg/mL and Coenzyme Q10 10-mg/mL Solution |
Vol. 12 No. 5 |
448 |
Dichlorobenzyl Alcohol Tooth Gel |
Vol. 12 No. 5 |
449 |
Estradiol 0.1% Vaginal Solution |
Vol. 12 No. 5 |
450 |
Flurandrenolide Topical Film |
Vol. 12 No. 5 |
451 |
Ketoprofen 20% Topical Solution |
Vol. 12 No. 5 |
452 |
Lidocaine Adhesive System Gel |
Vol. 12 No. 5 |
453 |
Piroxicam 5% and Dexpanthenol 5% Gel |
Vol. 12 No. 5 |
454 |
Propafenone 1.5-mg/mL Oral Liquid |
Vol. 12 No. 5 |
455 |
Testing the Long-Term Stability of Vancomycin Ophthalmic Solution |
Vol. 12 No. 5 |
456 |
Compatibility and Stability of Palonosetron Hydrochloride with Lactated Ringer's, Hetastarch in Lactated Electrolyte, and Mannitol Injections During Simulated Y-Site Administration |
Vol. 12 No. 5 |
460 |
Chemical Stability of Admixtures Combining Ziconotide with Fentanyl or Sufentanil During Simulated Intrathecal Administration |
Vol. 12 No. 5 |
463 |
PostScription: The International Society of Pharmaceutical Compounding: A Discussion of Its Importance from the Perspective of ISPhC Leadership |
Vol. 12 No. 5 |
467 |
Prescription: Is "Globalization" a Good Idea? |
Vol. 12 No. 6 |
474 |
Arthritis Epidemiology Impacts Pharmacists |
Vol. 12 No. 6 |
476 |
Compounding Challenges for Immunocompromised Patients |
Vol. 12 No. 6 |
482 |
Differentiation and Treatment of Hypothyroidism, Functional Hypothyroidism, and Functional Metabolism |
Vol. 12 No. 6 |
488 |
Case Reports: Compounding to Relieve Arthritis Pain |
Vol. 12 No. 6 |
498 |
Symbols: Historic and Current Uses |
Vol. 12 No. 6 |
505 |
Medication Therapy Management Implementation, Part 3: Barriers and Recommendations to Overcome Barriers |
Vol. 12 No. 6 |
508 |
Insurance for the Compounding Pharmacy Business, Part 2: What, When, and Where |
Vol. 12 No. 6 |
514 |
Quality-Control Analytical Methods: Overview of Beyond-Use Dating for Compounded Sterile Preparations |
Vol. 12 No. 6 |
524 |
Basics of Compounding: United States Pharmacopeia General Chapter <797> Pharmaceutical Compounding--Sterile Preparations, Part 10: First Revision: The Main Changes, Events, and Rationale |
Vol. 12 No. 6 |
530 |
Branding: Give Your Small Business a Big Image |
Vol. 12 No. 6 |
537 |
Calculations |
Vol. 12 No. 6 |
539 |
Cyclobenzaprine Hydrochloride 0.5% and Diclofenac Sodium 3% in Pluronic Lecithin Organogel |
Vol. 12 No. 6 |
540 |
Cyclobenzaprine Hydrochloride 1%, Dextromethorphan Hydrobromide 10%, Guaifenesin 10%, and Indomethacin 20% Penetrating Gel |
Vol. 12 No. 6 |
541 |
Glycerin, Sterile |
Vol. 12 No. 6 |
542 |
Indomethacin 2% in Pluronic Lecithin Organogel |
Vol. 12 No. 6 |
543 |
Ketorolac Tromethamine 2% Topical Gel |
Vol. 12 No. 6 |
544 |
Liothyronine Sodium (T3) 5-mcg/Hydrocortisone 5-mg Slow-Release Capsules |
Vol. 12 No. 6 |
545 |
Liothyronine Sodium (T3) 5-mcg/0.1-mL Transdermal Cream |
Vol. 12 No. 6 |
546 |
Liothyronine Sodium (T3) 5-mcg/Selenium 100-mcg Slow-Release Capsules |
Vol. 12 No. 6 |
547 |
Liothyronine Sodium (T3) 5-mcg Slow-Release Capsules |
Vol. 12 No. 6 |
548 |
Morphine Sulfate 20-mg and Prochlorperazine Maleate 10-mg Troches |
Vol. 12 No. 6 |
549 |
Physical Compatibility and Chemical Stability of a Concentrated Solution of Atropine Sulfate (2 mg/mL) for Use as an Antidote in Nerve Agent Casualties |
Vol. 12 No. 6 |
550 |
Chemical Stability of Admixtures Containing Ziconotide 25 mcg/mL and Morphine Sulfate 10 mg/mL or 20 mg/mL During Simulated Intrathecal Administration |
Vol. 12 No. 6 |
553 |
Stability of Metronidazole Benzoate in SyrSpend SF One-Step Suspension System |
Vol. 12 No. 6 |
558 |
PostScription: Supporting Compounding Around the World |
Vol. 12 No. 6 |
565 |